Time-Action Profile of Technosphere Insulin in Children with Type 1 Diabetes
- PMID: 36652106
- DOI: 10.1007/s13300-023-01368-7
Time-Action Profile of Technosphere Insulin in Children with Type 1 Diabetes
Abstract
Introduction: Technosphere insulin (TI) is an inhaled dry powder ultra-rapid-acting insulin. This report describes the results of the first study of TI in children with type 1 diabetes (T1D).
Methods: Pharmacokinetics (PK) of TI and the effect of TI on circulating glucose concentrations were evaluated in a single-arm study that enrolled children ages 8-17 years with T1D for more than 1 year, on a stable multiple daily insulin injection (MDI) regimen, and meeting pre-defined pulmonary function testing criteria (at least 70% predicted). To assess PK, subjects received an individualized single preprandial dose of TI (4-12 U, in 4-U increments) via oral inhalation, based on their usual meal-time subcutaneously injected rapid-acting insulin dose and meal content. Serum insulin and blood glucose were measured at - 30 to 250 min relative to dosing.
Results: Twenty-seven children with T1D participated in this single-dose PK study. Mean subject age was 13.3 years (59% female; 81.5% White). Mean serum insulin Cmax (maximum concentration) was 77.3, 119.15, and 207.7 µU/mL for doses of 4, 8, and 12 U, respectively. Tmax occurred at 10.5, 13.9, and 14.6 min post-dose for 4, 8, and 12 U. Glucose lowering 30-60 min post-dose was consistent with the PK profile.
Conclusion: Serum insulin rapidly increased post-dose and returned to baseline by 120 min. The data suggests the PK of TI in youth with T1D ages 8-17 years was similar to that seen in previous adult studies.
Trial registration: ClinicalTrials.gov identifier, NCT02527265.
Keywords: Inhaled insulin; Pediatric; Pharmacokinetics; Postprandial glucose; Type 1 diabetes.
© 2023. The Author(s).
Similar articles
-
Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes.J Diabetes Sci Technol. 2008 Mar;2(2):205-12. doi: 10.1177/193229680800200206. J Diabetes Sci Technol. 2008. PMID: 19885344 Free PMC article.
-
Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.Diabetes Technol Ther. 2018 Oct;20(10):639-647. doi: 10.1089/dia.2018.0200. Epub 2018 Sep 15. Diabetes Technol Ther. 2018. PMID: 30207748 Free PMC article.
-
Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes.J Diabetes Sci Technol. 2008 Jan;2(1):47-57. doi: 10.1177/193229680800200108. J Diabetes Sci Technol. 2008. PMID: 19885177 Free PMC article.
-
Place of technosphere inhaled insulin in treatment of diabetes.World J Diabetes. 2016 Dec 15;7(20):599-604. doi: 10.4239/wjd.v7.i20.599. World J Diabetes. 2016. PMID: 28031777 Free PMC article. Review.
-
Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.Diabetes Ther. 2020 Mar;11(3):573-584. doi: 10.1007/s13300-019-00732-w. Epub 2019 Dec 23. Diabetes Ther. 2020. PMID: 31873857 Free PMC article. Review.
References
-
- Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE Jr. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. 2020;41(50):733–55. - DOI
-
- Fiasp Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208751s000lbl.pdf . Accessed 2 Jan 2022.
-
- Lyumjev Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761109s000lbl.pdf . Accessed 2 Jan 2022.
-
- Lispro Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020563s115lbl.pdf . Accessed 2 Jan 2022.
-
- Slatterly D, Amiel SA, Choudhary P. Optimal prandial timing of bolus insulin in diabetes management: a review. Diabet Med. 2018;35(3):306–16. https://doi.org/10.1111/dme.13525 . - DOI